Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Current diagnosis of obstructive sleep apnea/hypopnea syndrome (OSAHS)~* Complaint of residual excessive sleepiness despite nasal continuous positive airway pressure (nCPAP) therapy being effective~* Current or prior diagnosis of major depressive disorder or dysthymic disorder~* Clinically stable with regard to depressed mood and has shown a treatment response to selective serotonin reuptake inhibitor (SSRI) therapy or serotonin and norepinephrine reuptake inhibitor (SNRI) therapy~* Patient has been on a stable monotherapy dose of an allowed SSRI or SNRI for at least 8 weeks at the time of screening~* Women of childbearing potential must use a medically accepted method of contraception.~Exclusion Criteria:~* Confirmed or suspected diagnosis of a currently active sleep disorder other than obstructive sleep apnea/hypopnea syndrome (OSAHS)~* Current episode of major depression that is considered to be treatment-resistant~* A primary diagnosis of: eating disorder, psychotic disorder, delirium, dementia, substance-related disorders, or moderate to severe hypochondriasis~* Patient has a history of bipolar disorder, psychotic depression, schizophrenia, schizoaffective disorder, any other psychotic disorder, or other clinically significant uncontrolled psychiatric condition.~* Patient has a history of homicidal ideation or significant aggression~* Patient has a diagnosis of severe antisocial or borderline personality disorder~* Has a history of significant suicidal ideation, or has current active suicidal ideation, or is considered at imminent risk of self harm.~* Patient has a history consistent with fibromyalgia or chronic fatigue syndrome~* A high consumption of caffeinated products, approximately equivalent to 5 or more cups of coffee per day~* Patient history of any clinically significant cutaneous drug reaction, or a history of clinically significant hypersensitivity reaction~* Has a past or present seizure disorder~* Patient has a history of alcohol, narcotic, or any other substance abuse or dependence (with the exception of nicotine)~* Psychotherapeutic intervention for the patient was initiated within 8 weeks of the screening visit.~* Patient has known human immunodeficiency virus (HIV)~* Patient has any clinically significant uncontrolled medical condition (including illnesses related to the cardiovascular, renal, or hepatic systems) or surgical condition (treated or untreated)~* Patient is a pregnant or lactating woman~* Patient has previously received armodafinil; or, patient has used modafinil or any investigational product within 28 days of the baseline visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): armodafinil 200 mg/day
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).